Gujarat Themis Biosyn Ltd (GUJTHEM) — shareholding pattern, promoter holding, financials and share price
About Gujarat Themis Biosyn Ltd (GUJTHEM)
Gujarat Themis Biosyn Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as GUJTHEM and on the BSE under scrip code 506879. Its ISIN is INE942C01045.
Incorporated in 1981, Gujarat Themis Biosyn Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process [1]
Gujarat Themis Biosyn Limited is a Vapi-based pharmaceutical company specialized in fermentation‑based intermediates and APIs, historically known for rifamycin intermediates and recently commissioned a multi-purpose API plant to forward‑integrate its value chain and target domestic and export markets.
The company reported Q3 FY26 revenue of Rs. 43.37 crore (up ~9.7% YoY) with an exceptionally high EBITDA margin of 49.1% in the quarter, reflecting tight cost optimization and volume growth despite higher manpower and depreciation costs during capex ramp-up.
Listed peers in Pharmaceuticals: RPG Life Sciences Ltd, Unichem Laboratories Ltd, Gufic BioSciences Ltd, SMS Pharmaceuticals Ltd, Novartis India Ltd, Aarti Drugs Ltd.
Valuation & Returns
10 Jul 2026At ₹379.55 a share on 10 Jul 2026, Gujarat Themis Biosyn Ltd (GUJTHEM) was valued at a price-to-earnings ratio of 88.62x against an industry P/E of 36.41x and a price-to-book of 16.65x on a book value of ₹22.79 per share as of Mar 2025. Solomo computes return on equity of 18.79% and return on capital employed of 23.32% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 88.62x
- Industry P/E
- 36.41x
- P/B
- 16.65x
- EPS (TTM)
- ₹4.28
- Book value / share
- ₹22.79
- ROE
- 18.79%
- ROCE
- 23.32%
- ROA
- 15.49%
- Debt / equity
- 0.12x
- Dividend yield
- 0.18%
- EBITDA margin
- 47.01%
- 52-week range
- ₹225.75 – ₹479.45
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Gujarat Themis Biosyn Ltd (GUJTHEM) reported revenue of ₹166 crore, net profit of ₹47 crore and earnings per share of ₹4.28. That compares with revenue of ₹151 crore and net profit of ₹49 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹44 crore and net profit ₹11 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 115 | 148 | 170 | 151 | 166 |
| Net profit (₹ cr) | 44 | 58 | 59 | 49 | 47 |
| EPS (₹) | 4 | 5.32 | 5.43 | 4.48 | 4.28 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 18.54% | 12.12% | 9.50% | -11.20% |
| Profit growth | 29.91% | 15.55% | 3.79% | -17.56% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 70.86% of Gujarat Themis Biosyn Ltd (GUJTHEM) (unchanged from the previous quarter), foreign institutional investors (FII) hold 1.77% and domestic institutional investors (DII) hold 1.18%. Promoters have pledged 5.4% of their holding. Market capitalisation was ₹4,136 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Quant Mutual Fund - Quant Manufacturing Fund 1.15%, Ayushmat Ltd 1.12%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 70.86% | 5.4% | 1.77% | 1.18% | 29.14% |
| Mar 2026 | 70.86% | 5.4% | 1.8% | 1.18% | 29.14% |
| Dec 2025 | 70.86% | 4.5% | 1.96% | 1.17% | 29.14% |
| Sep 2025 | 70.86% | 3.3% | 2.95% | 1.17% | 29.14% |
| Jun 2025 | 70.86% | 3.3% | 2.51% | 1.17% | 29.14% |
| Mar 2025 | 70.86% | 3.3% | 1.91% | 1.17% | 29.14% |
| Dec 2024 | 70.86% | 3.3% | 1.42% | 1.17% | 29.14% |
| Sep 2024 | 70.86% | 3.3% | 1.49% | 1.17% | 29.14% |